What's happened?
Amplia Therapeutics Limited (ATX:ASX, "Amplia") have made a key addition to their Scientific Advisory Board.
What are the key highlights?
Professor Paul Timpson has been appointed to Amplia's Scientific Advisory Board. Professor Timpson leads the Invasion and Metastasis Lab at the Garvan Institute of Medical Research and is a world leader in FAK biology. As a member of Amplia’s SAB, Professor Timpson will contribute his advice and experience to the design of the Company’s planned clinical studies so that they are designed with the very latest understanding of FAK biology in mind.
